Microscopic colitis (MC) is a chronic inflammatory bowel condition characterized by chronic watery diarrhea and diagnosed with the histologic hallmarks of disease despite a macroscopically normal large bowel. Although 2 distinct disease phenotypes exist, their clinical presentations and epidemiologic characteristics have overlapping features. This article summarizes evidence regarding the pathogenesis of MC, mechanisms of diarrhea in this cohort, and associations with medications. In addition, currently recommended and novel therapeutic approaches to achieving remission in this patient population are reviewed.

Incidence and Risk Factors

The reported prevalence rates of CC and LC are 42 and 69 per 100,000 persons, respectively, and the incidence rates of these diseases in patients under investigation for chronic diarrhea are higher, from 10% to 20%. Established risk factors include increasing age, with 75% of the people affected being over 50 years old. The ratio of women to men is 2.4 to 1, and women have a proportionally greater risk of CC. A recent French study reported...
that the incidence of MC was 7.9 per 100,000 inhabitants, similar to the incidence of Crohn's disease in that population. Although a history of smoking is associated with transient risk, current smoking increases the risk of persistent disease and CC diagnosis at a young age (odds ratio [OR], 2.4; 95% CI, 1.5-3.8). In addition, a history of autoimmune disease, including diabetes mellitus, rheumatoid arthritis, and celiac sprue, is associated with MC. Celiac disease is associated with a 50 to 70 times greater risk of MC, especially in middle-aged women, and with severe villous atrophy. In a multicenter, prospective study of 433 patients with MC or functional diarrhea, Macaigne and colleagues found that MC was associated with age over 50 years (OR, 3.1; 95% CI, 1.6-5.9), nocturnal diarrhea (OR, 2.0; 95% CI, 1.1-3.9), weight loss (OR, 2.5; 95% CI, 1.3-4.7), new medications (OR, 3.7; 95% CI, 2.1-6.6), and autoimmune disease (OR, 5.5; 95% CI, 2.5-12.0). Macaigne and colleagues found that MC was associated with age over 50 years (OR, 3.1; 95% CI, 1.6-5.9), nocturnal diarrhea (OR, 2.0; 95% CI, 1.1-3.9), weight loss (OR, 2.5; 95% CI, 1.3-4.7), new medications (OR, 3.7; 95% CI, 2.1-6.6), and autoimmune disease (OR, 5.5; 95% CI, 2.5-12.0).

Etiology

Dysregulated Collagen Metabolism

In CC, collagen accumulation in the subepithelial layer reflects disturbance in the homeostasis of the extracellular matrix and is predominantly driven by attenuated matrix degradation and tissue inhibitor of metalloproteinase-1 (TIMP-1) imbalance. This inhibits several metalloproteinases involved in collagen degradation and upregulation of transforming growth factor-β, which contributes to fibrogenesis and collagen deposition. Vascular endothelial growth factor is implicated in repair mechanisms in MC with increased tissue immunostaining in remission, counteracting TIMP-1 activity and facilitating collagen breakdown through innate metalloproteinases.

Abnormal Epithelial Barrier Function

Histology before and after ileostomy reversal found increased transcellular and tight junction permeability, proposing that mucosal barrier dysfunction has a role in CC. Gastrointestinal luminal interleukin-2, -23, -12 levels rise after restoration of intestinal continuity, supporting the idea that luminal toxins drive inflammation in CC. Furthermore, downregulation of the tight junction proteins claudin-4, -5, and -8, and their redistribution off the tight junction, triggered by tumor necrosis factor-α (TNF-α) and interferon-γ, contribute to diarrhea in LC.

Drug Exposure and Microscopic Colitis

Medications associated with MC include nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin; selective serotonin reuptake inhibitors; proton pump inhibitors (PPIs); and drugs with various other mechanisms of action, including statins, beta blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers. Multidrug use, particularly concomitant NSAIDs and PPIs, further increases the risk of MC. MC does not progress in a dose-dependent manner, and symptoms may be reported days to months after drug initiation, with a median time of 4 days to symptom onset.

A retrospective case-control study of 136 patients with MC reported that 38% of CC patients had a history of PPI use, yielding an OR of 4.5 vs matched controls for MC. Controlling for celiac disease, hypothyroidism, and rheumatoid arthritis in multivariate analysis, the OR increased to 5.8. PPIs alter intestinal microbial communities and induce acid suppression as well as increase intercellular permeability, which may contribute to disease given the known tight junction dysfunction in MC.

In summary, there is evidence to suggest that certain drugs may precipitate the onset of MC, and there should be consideration to stop these drugs to reduce the risk of relapse.

Clinical Features

There is considerable overlap in the clinical presentations of LC and CC. The natural histories of these diseases are variable, with reports of occasional spontaneous remission of symptoms with eventual recurrence, often without an identifiable trigger. A retrospective analysis of 199 patients reported a median 6-month disease duration in LC patients until treatment. Symptoms may vary from mild chronic watery diarrhea to incapacitating, increased stool frequency, and urgency and fecal incontinence. Stool consistency is very loose, with 88% of MC patients having a median stool form of 6 on the Bristol Stool Scale, compared with 35% of patients with functional diarrhea. Patients with MC have features of both secretory and osmotic diarrhea. Marked reduction in stool frequency may occur in response to reduced oral intake, suggesting an osmotic component. Secretory features seem to be driven by active chloride secretion, and analysis of fecal electrolytes reveals increased fecal fluid sodium and potassium concentration, with 87% of MC patients meeting the diagnostic criteria for secretory diarrhea. It is likely that reduced sodium absorption drives diarrhea in LC, contrasting with increased chloride secretion and reduced rates of bicarbonate/chloride exchange in CC. In LC, chromogranin (Cg) A–positive cells are present in the epithelial layer at higher density, possibly suggesting a role of colonic neuroendocrine cells in chronic diarrhea. Higher levels of fecal neuroendocrine peptides, including secretoneurin, CgA, and CgB, are present in active CC, and secretoneurin levels revert in clinical remission to values comparable to those.
of healthy controls. However, the diagnostic utility of these peptides has not been established.

Approximately half of the affected population will report some weight loss or abdominal pain. A meta-analysis of 10 published studies has refuted perceptions that there is a link between MC and irritable bowel syndrome (IBS). In the analysis, the pooled prevalence was 33.4% (13.8%-55.7%) for IBS in MC, not a significantly greater prevalence than in chronic functional diarrhea (OR, 1.39). Considered separately or pooled together, patients with IBS did not have increased odds of diagnosis with MC. A daily stool frequency of more than 3 motions per day in CC patients is associated with reduced health-related quality-of-life scores. Therefore, improvement in quality of life is often included as a measure of clinical response and remission in therapeutic efficacy studies. There are few cases of severe complications, including amyloidosis with subsequent colon stricturing and ulceration due to long-standing inflammation, protein-losing enteropathy with hypoalbuminemia, and spontaneous colonic perforation in individual cases of CC.

**Diagnosis**

Laboratory investigations often have normal or mildly deranged findings in patients with MC and offer limited diagnostic value. Approximately 50% of MC patients have mild anemia and mildly elevated inflammatory markers. Objective fecal biomarkers such as fecal calprotectin are not reliable indicators of MC. Although the median fecal calprotectin level was higher in MC patients in 2 small studies of active MC vs functional diarrhea, the absolute fecal calprotectin level was low, between 48 to 80 μg/g, and up to 38% of patients with active disease had a normal calprotectin level, limiting its use to reliably differentiate between MC and functional diarrhea. Fecal lactoferrin, also of neutrophilic origin, has very low sensitivity in MC patients, with only 10% having increased levels in an analysis of 39 patients.

Histologic hallmarks of disease in microscopically unremarkable colon form the diagnostic cornerstone in MC. Colonoscopy and biopsies of the right and left colon are recommended; when only left-sided sampling is performed, the diagnosis can be missed in up to 40% of patients due to the reduction in histologic burden from proximal to distal colon. However, subsequent research has suggested that up to 97.5% of cases could be diagnosed with only left colon biopsies. In cases of diagnostic uncertainty, CD3 staining may accurately quantify the extent of intraepithelial lymphocytosis. A third entity, incomplete MC or MC not otherwise specified, has been identified, describing a cohort with chronic diarrhea and classic pathologic features not meeting diagnostic criteria for LC or CC. These cases have responded to standard MC therapies, including budesonide.

**Treatment of Microscopic Colitis**

If medications are implicated in individual MC cases, withdrawal alone is usually insufficient to achieve clinical response. These patients usually require medical treatment to achieve remission. Randomized, controlled trials and meta-analyses favor budesonide for induction of clinical remission. A Cochrane systematic review reported an OR of 12.32 to induce and 8.82 to maintain response in CC over 6 months with a number needed to treat (NNT) of 2 per outcome. A minority of patients achieve histologic remission. Similar response rates were seen in LC with an OR of 9 to induce response and a NNT of 3. Budesonide improves quality-of-life scores using the gastrointestinal quality-of-life index. American Gastroenterological Association (AGA) guidelines recommend an 8-week course of budesonide as first-line therapy for induction of clinical remission based on a meta-analysis of 6 studies showing a net beneficial effect and 152% increase in the likelihood of remission over 6 to 8 months. Data supporting the use of oral prednisolone for induction of remission are modest, so its use is not recommended as first-line treatment, particularly considering the side-effect burden associated with corticosteroids. An analysis of 17 patients treated with prednisolone vs 63 with budesonide showed lower remission rates and increased relapse with prednisolone.

Clinical relapse after stopping budesonide is common and reported in 40% to 81% as soon as 2 weeks after withdrawal. Analysis of predictors of recurrence identified risk factors, including older patients (>60 years), longer duration of symptoms (>12 months), and high daily stool frequency (>5/day). Maintenance therapy with oral budesonide may be required to restore quality of life and maintain clinical remission in a proportion of patients. Maintenance therapy with 4.5 mg of budesonide daily was associated with maintenance of remission, sustained improvement in quality-of-life scores for CC patients, and nonserious adverse effects in 7 of 44 patients. Little research has examined the success rates of budesonide for maintenance of remission in LC. Although minimal side effects have been reported in MC during budesonide therapy, the association between long-term budesonide use and reduced bone density scores in Crohn’s disease underscores the importance of monitoring bone health in these patients. For maintenance, the lowest effective dose of budesonide should be used. Consideration should also be given to the specific budesonide formulation used. The preferred
form of budesonide is absorbed in the ileum and right colon, rather than the alternative, which is associated with mainly left colon absorption and, hence, may be less effective in MC.57

The AGA recommends that treatment with mesalamine or bismuth subsalicylate should be considered over no treatment when budesonide is contraindicated or fails.57 Treatment with bismuth subsalicylate was associated with favorable clinical outcomes in a small open-label study of LC and CC resulting in clinical and histologic responses.64 Clinical efficacy studies of mesalamine have yielded mixed results, finding this therapy inferior to budesonide for induction of remission (relative risk [RR], 1.82 for remission with budesonide vs mesalamine).4,65 Although mesalamine is recommended as second-line therapy in MC, the clinical data available do not strongly support this recommendation. In LC, mesalamine in combination with cholestyramine did not significantly increase the likelihood of achieving clinical remission, although in CC, dual therapy was associated with a greater chance of remission than mesalamine alone. The modest increased response was offset by adverse effects.66 Despite morphologically normal distal ileum, bile acid malabsorption has been identified in approximately 40% of MC patients in 2 studies, with induction of clinical remission following cholestyramine in 19 of 22 patients with abnormal 75Se-homocholic acid taurine scans.67,68 In the absence of bile acid malabsorption, there is weak evidence for clinical response to cholestyramine. These recommendations are limited by a lack of controlled clinical trials for these drugs, with the exception of bismuth and budesonide, and some mixed

Figure. An algorithm of diagnostic and therapeutic recommendations for patients with microscopic colitis.

BMIs, bowel movements; TNF, tumor necrosis factor.
Biotics have a place within the clinical paradigm. Clinical trials would be useful to determine whether probiotics have a place within the clinical paradigm.

Refractory Microscopic Colitis

Some patients may have persistent symptoms despite medical therapy. In these individuals, coexistent conditions such as celiac disease should be first excluded. If contraindicated, or relapse occurs despite budesonide maintenance, immunomodulators (azathioprine and 6-mercaptopurine) are reasonably efficacious in MC, although their use may be limited by intolerance in approximately one-third of patients in this setting. Methotrexate has been used with mixed results in retrospective and prospective analyses, although inadequate power may have influenced the outcome. Similarly, calcineurin inhibitors have been used in individual reports and were well tolerated, but only 1 patient achieved complete response. These drugs are not currently recommended in refractory MC.

A case series points to the use of anti–TNF-α agents in refractory disease. Excellent early response rates have been reported, with a reduction of daily stool frequency of up to 90% and sustained remission in a proportion of patients. One analysis over almost 20 years included 10 patients treated with anti–TNF-α therapy for a median of 4 months, and reported that a proportion of patients achieved partial response to anti–TNF-α therapy. Long-term use in MC may not be necessary if a precipitating agent such as a PPI has been identified and discontinued.

Colectomy and consequent diversion of the fecal stream have been used to treat a small cohort of patients with medically refractory MC. A case of LC and a case of CC successfully treated with colectomy and subsequent fashioning of ileal J-pouch have been reported. Although histologic remission does not always coexist with clinical remission after medical therapy, diversion of the fecal stream resolves histologic changes, which recur after ileostomy reversal.

Summary

In an aging population, the prevalence of MC is likely to rise, and recent guidelines provide clarity and clear approaches for management of this disease. Although serious and life-threatening complications are uncommon, symptoms may be debilitating and negatively impact quality of life for elderly patients. A high index of suspicion is required in female patients over 50 years old reporting chronic watery diarrhea, particularly with a history of autoimmune or celiac disease. Careful histories are recommended to identify possible triggers, especially in patients taking multiple medications for comorbidities. Budesonide remains the recommended first-line therapy, and maintenance therapy with the drug is often required.

The authors have no relevant conflicts of interest to disclose.

References

Inflamm Bowel Dis. 2013;21(9):6065-6071.


